453 related articles for article (PubMed ID: 24012660)
1. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
2. Drugs targeting Bcl-2 family members as an emerging strategy in cancer.
Leber B; Geng F; Kale J; Andrews DW
Expert Rev Mol Med; 2010 Sep; 12():e28. PubMed ID: 20822554
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
4. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
5. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Khaw SL; Huang DC; Roberts AW
Pathology; 2011 Oct; 43(6):525-35. PubMed ID: 21881535
[TBL] [Abstract][Full Text] [Related]
6. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
9. Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer.
Mei H; Lin Z; Wang Y; Wu G; Song Y
Neoplasma; 2014; 61(2):186-92. PubMed ID: 24299314
[TBL] [Abstract][Full Text] [Related]
10. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2.
Liu Y; Zhang Z; Song T; Liang F; Xie M; Sheng H
Br J Pharmacol; 2013 Aug; 169(7):1612-23. PubMed ID: 23651505
[TBL] [Abstract][Full Text] [Related]
11. Subversion of the Bcl-2 life/death switch in cancer development and therapy.
Adams JM; Huang DC; Strasser A; Willis S; Chen L; Wei A; van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S
Cold Spring Harb Symp Quant Biol; 2005; 70():469-77. PubMed ID: 16869785
[TBL] [Abstract][Full Text] [Related]
12. The novel small molecular BH3 mimetics SM3 and its regulation of cell apoptosis and autophagy.
Wang Y; Fan S; Li X; Xiaokaiti Y; Pan Y; Tie L; Li X
Biochem Biophys Res Commun; 2019 Sep; 517(1):15-22. PubMed ID: 31303271
[TBL] [Abstract][Full Text] [Related]
13. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.
Vela L; Marzo I
Curr Opin Pharmacol; 2015 Aug; 23():74-81. PubMed ID: 26079328
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
Goldsmith KC; Hogarty MD
Curr Opin Investig Drugs; 2009 Jun; 10(6):559-71. PubMed ID: 19513945
[TBL] [Abstract][Full Text] [Related]
17. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
18. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
19. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]